Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL11 Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CXCL11 Products |
| Gene Delivery | CXCL11 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and in vitro functional expression. |
View CXCL11 Products |
| Benchmark Ab | Anti-CXCL11 Recombinant Antibody Recombinant positive control matching clinical benchmark sequence. |
View CXCL11 Products |
| Validator | CXCL11 siRNA Set For target knockdown validation in primary cells or cell lines. |
View CXCL11 Products |
| Related Target A | CXCR3 The primary G-protein coupled receptor for CXCL11, mediating chemotaxis of activated T cells and NK cells. |
View CXCR3 Products |
| Related Target B | ACKR3 Also known as CXCR7, a scavenger receptor that binds CXCL11 with high affinity, modulating its extracellular gradient. |
View ACKR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity Assessment | Human, Mouse, and Cynomolgus CXCL11 ortholog proteins available with >95% purity verified by SDS-PAGE |
| Receptor Selectivity & Off-Target Screening | Homolog panel including CXCL9 and CXCL10 proteins strictly verified by Mass Spectrometry to prevent cross-contamination |
| Lack of Validated Control Reagents | Clinical Benchmark Antibodies (Biosimilars) sequence-verified and produced in mammalian systems |
| Target Specificity Validation | Sequence-verified siRNA pools included for precise target knockdown and specificity controls |
Live CXCL11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCL11 therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory mAbs to localized chemokine modulation in oncology. As first-generation therapies targeting the CXCR3/CXCL11 axis reach the clinic, the next wave of R&D is targeting the recruitment of tumor-infiltrating lymphocytes (TILs) to turn "cold" tumors "hot."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Antagonists) | Bristol Myers Squibb, Sanofi | Inflammatory Bowel Disease, Multiple Sclerosis | Receptor-binding inhibition assays (Need high-purity, native-conformation CXCL11) |
| Oncolytic Viruses / mRNA (Agonists) | Amgen, Transgene | Solid Tumors (combination with PD-1/PD-L1) | In vitro chemotaxis validation (Need stable HEK293-expressed CXCL11 protein) |
| Small Molecule Antagonists | ChemoCentryx, Actrum | Autoimmune Diseases, Rheumatoid Arthritis | Selectivity profiling against CXCR3/CXCR7 (Need Lentivirus for Stable Cell Lines) |